2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic …
ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …
that, unless otherwise provided for by national regulations, offlabel use of medication should …
Venous and Arterial Thromboembolism in Patients With Cancer: JACC: CardioOncology State-of-the-Art Review
Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism,
represents a major cause of morbidity and mortality in patients with cancer. Arterial …
represents a major cause of morbidity and mortality in patients with cancer. Arterial …
Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update
PURPOSE To provide updated recommendations about prophylaxis and treatment of
venous thromboembolism (VTE) in patients with cancer. METHODS PubMed and the …
venous thromboembolism (VTE) in patients with cancer. METHODS PubMed and the …
[HTML][HTML] Cancer-associated thrombosis: enhanced awareness and pathophysiologic complexity
A Falanga, M Marchetti - Journal of Thrombosis and Haemostasis, 2023 - Elsevier
Thrombosis, both venous and arterial, is a leading cause of morbidity and mortality in
patients with cancer. Studies on the molecular basis of cancer-associated thrombophilia …
patients with cancer. Studies on the molecular basis of cancer-associated thrombophilia …
Cancer-associated venous thromboembolic disease, version 2.2021, NCCN clinical practice guidelines in oncology
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer-Associated
Venous Thromboembolic Disease focus on the prevention, diagnosis, and treatment of …
Venous Thromboembolic Disease focus on the prevention, diagnosis, and treatment of …
A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts
Background Venous thromboembolism is a common complication of cancer, but the risk of
develo** venous thromboembolism varies greatly among individuals and depends on …
develo** venous thromboembolism varies greatly among individuals and depends on …
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at a high risk of VTE recurrence and bleeding during …
cancer. These patients are at a high risk of VTE recurrence and bleeding during …
A clinical-genetic risk score for predicting cancer-associated venous thromboembolism: a development and validation study involving two independent prospective …
PURPOSE Venous thromboembolism (VTE) is a leading cause of death among patients with
cancer. The Khorana score was developed for assessing the risk of VTE in outpatients with …
cancer. The Khorana score was developed for assessing the risk of VTE in outpatients with …
Mechanisms and biomarkers of cancer-associated thrombosis
Cancer-associated thrombosis is a leading cause of non-cancer death in cancer patients
and is comprised of both arterial and venous thromboembolism (VTE). There are multiple …
and is comprised of both arterial and venous thromboembolism (VTE). There are multiple …
Derivation and validation of a clinical risk assessment model for cancer-associated thrombosis in two unique US health care systems
PURPOSE Venous thromboembolism (VTE), especially pulmonary embolism (PE) and
lower extremity deep vein thrombosis (LE-DVT), is a serious and potentially preventable …
lower extremity deep vein thrombosis (LE-DVT), is a serious and potentially preventable …